The American Psychiatric Association has issued the first guidelines to help psychiatrists with manic-depressive patients. It took two years to develop the guidelines, which call for long-term psychiatric care and use of some drugs.
While the guidelines state that there is no cure for the disease, the APA noted that up to 80% of patients with the illness will see significant improvement with appropriate treatment. Among the APA's recommendations are that:
- lithium helps 80% of patients by preventing manic-depressive episodes and calming mood instability;
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze